Pharmaceuticals & Therapeutics

With its European trial launch, Kainova's DT-7012 aims to disarm cancer's bodyguards, offering new hope for patients with advanced solid tumors.

Treating over 100,000 patients in two years, a novel gel therapy is leading a paradigm shift in interventional dry eye management. Here's how.

Eli Lilly's new once-daily oral GLP-1, Foundayo, is now on telehealth platform Ro, offering a convenient, needle-free alternative to injectable drugs.

Following a massive stock surge, Forte Biosciences is raising $150M. The funds are crucial for a pivotal year of clinical trials for its autoimmune drug.

Absci will showcase its generative AI drug discovery platform at a key healthcare conference, highlighting its ambitious pipeline for hair loss and endometriosis.

With its future riding on a pivotal trial for avexitide, Amylyx's upcoming conference presentation offers a crucial look into its post-ALS strategy.

Altruist Biologics secures a landmark license for China's largest bioreactor facility, signaling a major shift in the global biopharmaceutical supply chain.

With a $137M war chest, Sidewinder Therapeutics is advancing a new class of ultra-precise cancer drugs aimed at tumors that have long evaded treatment.

Blue Faery recognizes two doctors whose groundbreaking research in immunotherapy and targeted drugs has created new standards of care for liver cancer patients.

The dermatologist-founded brand is expanding access to clinical-grade treatments for underserved skin concerns, signaling a major shift in the industry.

Hemispherian launches a landmark trial for GLIX1, a first-in-class therapy aiming to selectively destroy glioblastoma cells where others have failed.

A new alliance between Daiichi Sankyo and ATLATL aims to leverage a unique 'Super Server' model to fast-track novel therapies from Asia to the world.

Lupin wins FDA approval for its generic dapagliflozin, a move set to slash costs for a blockbuster diabetes and heart drug and reshape patient care.

After three rejections, Outlook Therapeutics escalates its fight for US approval of a key wet AMD drug, already sold in Europe. Will the FDA bend?

A strategic partnership with 5 Horizons Ventures accelerates Marvel Biosciences' novel drug, MB-204, into human trials for autism, Rett syndrome, and more.

Early Phase 3 results show gotistobart dramatically extends survival for lung cancer patients with limited options, heralding a potential new standard of care.

A new bispecific antibody aims to treat the 50% of AxSpA patients who find no relief, as Fortitude Biomedicines enters a competitive autoimmune market.

A new partnership brings a groundbreaking protocol for corneal blindness to Chicago, expanding a national network dedicated to restoring vision for thousands.

As employers face staggering GLP-1 expenses, a new program aims to deliver measurable outcomes by integrating clinical support directly into pharmacy benefits.

Eosera just unveiled its largest product launch ever, aiming to become the authority in a growing OTC market with new solutions for pain, itch, and wellness.